Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR 15 versus XELSTRYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR 15 versus XELSTRYM.
DYANAVEL XR 15 vs XELSTRYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR contains amphetamine, which is a central nervous system stimulant that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
XELSTRYM (dextroamphetamine transdermal system) is a sympathomimetic amine that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
1-3 capsules orally once daily in the morning. Each capsule contains 15 mg of amphetamine (equivalent to 15 mg dextroamphetamine/amphetamine).
Initial: one 9-mg patch applied to the hip once daily; titrate weekly in 4.5-mg increments to desired effect; maximum dose: 18 mg/day.
None Documented
None Documented
Terminal elimination half-life: amphetamine (d-isomer) 9-11 hours, l-isomer 11-14 hours; allows for once-daily dosing in extended-release formulation
Mean terminal elimination half-life of dexmethylphenidate is approximately 2-3 hours in children and adolescents, with no significant accumulation at steady state; clinical effects correlate with plasma concentrations.
Renal (80-90% as unchanged drug and metabolites, primarily dehydro-amphetamine); fecal excretion minimal (<5%)
Renal (90% as unchanged drug and metabolites, primarily dehydrodexmethylphenidate and inactive metabolites); minor biliary/fecal elimination (<5%)
Category C
Category C
CNS Stimulant
CNS Stimulant